Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX)
Rhea-AI Filing Summary
Moti Investments LLC is reported as a significant shareholder of Elicio Therapeutics, Inc., with beneficial ownership of 1,408,892 shares of common stock, par value $0.01 per share. This position represents 6.1% of Elicio’s common stock class.
Moti Investments, organized in Saint Kitts and Nevis and based in Dubai, has sole voting power and sole dispositive power over all 1,408,892 shares, with no shared voting or dispositive power. The report is signed by Manager Kalpana H. Jogani, dated July 16, 2026.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 1,408,892 shares
Ownership percentage: 6.1%
Sole voting power: 1,408,892 shares
+3 more
6 metrics
Beneficially owned shares
1,408,892 shares
Common Stock beneficially owned by Moti Investments LLC
Ownership percentage
6.1%
Percent of Elicio Therapeutics common stock class held by Moti Investments LLC
Sole voting power
1,408,892 shares
Shares for which Moti Investments LLC has sole power to vote or direct the vote
Shared voting power
0 shares
Shares for which Moti Investments LLC has shared power to vote
Sole dispositive power
1,408,892 shares
Shares for which Moti Investments LLC has sole power to dispose or direct disposition
Shared dispositive power
0 shares
Shares for which Moti Investments LLC has shared power to dispose
Key Terms
beneficially owned, sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, Schedule 13G
4 terms
beneficially owned financial
"Ownership (a) | Amount beneficially owned: 1,408,892"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole power to vote or to direct the vote financial
"Number of shares as to which the person has | (i) Sole power to vote or to direct the vote"
sole power to dispose or to direct the disposition financial
"(iii) Sole power to dispose or to direct the disposition of: 1,408,892"
Schedule 13G regulatory
"Elicio Therapeutics, Inc. ... SCHEDULE 13G ownership report by Moti Investments LLC"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake does Moti Investments LLC report in Elicio Therapeutics (ELTX)?
Moti Investments LLC reports beneficial ownership of 1,408,892 Elicio Therapeutics common shares, representing 6.1% of the class. This Schedule 13G reflects a significant shareholder position with sole voting and dispositive power over all reported shares.
What percentage of Elicio Therapeutics (ELTX) common stock is owned by Moti Investments?
Moti Investments LLC reports holding 6.1% of Elicio Therapeutics’ common stock class. This percentage is based on 1,408,892 shares beneficially owned, as disclosed in the Schedule 13G ownership section for the company’s common stock.
Who signed the Schedule 13G for Moti Investments LLC regarding Elicio Therapeutics (ELTX)?
The Schedule 13G is signed by Kalpana H. Jogani, in the capacity of Manager of Moti Investments LLC. The signature section shows the execution date as July 16, 2026, confirming the certification of the reported ownership details.
What class of Elicio Therapeutics (ELTX) securities is reported by Moti Investments?
Moti Investments LLC reports holdings in Elicio Therapeutics’ Common Stock, par value $0.01 per share. The Schedule 13G lists this security class along with the CUSIP 28657F103 as the subject of the reported beneficial ownership.